Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03553836
Recruitment Status : Active, not recruiting
First Posted : June 12, 2018
Last Update Posted : November 12, 2020
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.